Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...
The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback